Thank you, Rep. Don Beyer for supporting the FY24 proposed NIH Appropriation increase for Alzheimer’s specific research. Your support for the mission to #ENDALZ is greatly appreciated. @RepDonBeyer
I met with Rep. Don Beyer’s Community Relations Coordinator, Richard Cerros, to request that Mr. Beyer be a co-sponsor of NAPA HR619, AAIA HR 620 and the BOLD ACT HR7218. These bills will strengthen the mission to #ENDALZ@RepDonBeyer
@davidm_cook David, I am so sorry. I understand how difficult this must be on you and your family. I know your care for and support of your Dad must be comforting to your Mom. She’s fortunate to have you by her side and your Dad’s.
As you travel this Labor Day weekend, know that several airports across the US have developed and implemented operational and assistive procedures for those passengers living with Alzheimer’s and/or related cognitive conditions.
Look https://t.co/GWDA22X62h
Good news within the Alzheimer's community-- @CMSGov has developed a test model to improve the delivery of care for those living with Alzheimer's. Many thanks to the Biden Administration for their work and support of this project.
We enthusiastically welcome the Biden Administration’s announcement of a new @CMSGov test model to improve the way dementia care is delivered for people living with Alzheimer’s disease & other dementia. Read our statement: https://t.co/97uNGFDcQ3
Thank you @RepMaxineWaters and Chris Smith for leading 79 bipartisan Representatives in sending a letter of support for a $321 million increase in funding for Alzheimer’s research at the @NIH in FY 2024. View the letter here: https://t.co/PTRzJwpf5Y
@SecBecerra, those that have ALZ, their families and caregivers deserve a clear and consistent explanation, no meaningless lip-service, about the denial of access to FDA approved ALZ drugs. Demand @CMSGov allow access to these drugs NOW! @RepDonBeyer
Retweet if you want @POTUS to fight @CMSGov’s decision to block access to FDA-approved treatments for people living with early Alzheimer’s. People with Alzheimer’s deserve #MoreTime!
We're closing out March by celebrating our own @joannepikedrph. She makes history as our first woman CEO. As a leader in public health, Dr. Pike is focused on advancing care & research priorities that will have real impact on those facing Alzheimer’s. #WomensHistoryMonth#ENDALZ
@SecBecerra, if you won’t allow access to FDA approved ALZ drugs to all, then new label: “FDA AND VA HEALTH APPROVED; CMS/MEDICARE-NOT SO MUCH. CMS AND FDA 2 DIFFERENT ANIMAL, SO…SORRY!” Funny if it wasn’t so sad and harmful. ACCESS NOW!
@SecBecerra, without your release of FDA approved ALZ drugs to those who need it, new labeling is necessary: WARNING: FDA AND VA HEALTH APPROVED. CMS/MEDICARE, NOT SO MUCH,SORRY "2 DIFFERENT ANIMALS" This would be funny if not so sad and serious. @CMSGov
@SecBecerra, your minimal responses to the urgent requests for access to all FDA approved ALZ drugs for those on Medicare is disappointing. Your refrain of FDA and CMS are 2 different animals with different standards of approval is not adequate explanation. @RepDonBeyer
Thank you, @RepJohnJoyce for your supportive comments regarding the urgent need to release FDA approved drugs for treatment of Alzheimer’s. CMS should not be allowed to block those drugs for those on Medicare. @RepDonBeyer